The trajectory of copyright's flagship drug presents a interesting case for investors in the pharmaceutical sector. While initially a blockbuster success, generating huge profits, the patent end and the subsequent arrival of cheaper competitors have considerably affected revenue. This raises questions about the ongoing sustainability of related med